HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: IFRA's New Fragrance Standards; 'Green Beauty Barometer' Results; More

This article was originally published in The Rose Sheet

Executive Summary

The International Fragrance Association releases the 48th Amendment to its Code of Practice, which includes new standards derived via Quantitative Risk Assessment to minimize dermal-sensitization risks. In other news, market research firms highlight survey results underscoring the influence of "all-natural" marketing and celebrity endorsements on personal-care purchasing habits.

You may also be interested in...



Industry Groups Keeping Eye On Montana’s Fragrance-Disclosure Bill

The International Fragrance Association North America and Personal Care Products Council are monitoring state-level proposals in the US to require full fragrance ingredient disclosure, including a Montana bill that passed committee in February. IFRA NA head Farah Ahmed discusses the group’s related advocacy work.

QUOTED. 30 September 2020. Andrew Newlands.

ANGLE plc’s Parsortix system could become the first FDA-cleared device for harvesting intact cancer cells from a blood sample. See what CEO Andrew Newlands said about its potential benefits.

One Goal, Four Paths: Comparing COVID-19 Vaccine Pivotal Trial Protocols

Phase III protocols for COVID-19 vaccine candidates from Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson are similar – but definitely not the same.

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel